亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

萊陽市宇辰技術研發所  

醫藥中間體,原料藥,東莨菪醇

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:郭婷婷
  • 電話:0535-7290068
  • 郵件:sdycc1234@163.com
  • 傳真:0535-7290068
  • QQ:947049894
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 東莨菪醇 498-45-3
東莨菪醇 498-45-3
單價 面議對比
詢價 暫無
發貨 山東煙臺市付款后3天內
庫存 1000000克起訂1克
品牌 萊陽宇辰
型號 498-45-3
規格 97
過期 長期有效
更新 2017-02-27 15:00
 
詳細信息
中間體 scopine東莨菪醇     498-45-3    ≥97%   白色或類白色粉末
中間體 scopine hydrochloride 東莨菪醇鹽酸鹽 85700-55-6   ≥97%    白色或類白色粉末
中間體Scopolamine Hydrobromide 東莨菪堿氫溴酸鹽   114-49-8   ≥99% 白色或類白色粉末
中間體Scopolamine Butyl Bromide (Hyoscine N-Butyl Bromide) 東莨菪堿丁溴酸鹽 149-64-4   ≥99% 白色或類白色粉末
中間體 Ethyl piperidine-4-carboxylate 4-哌啶甲酸乙酯(鹽酸鹽)   1126-09-6   ≥99% 哌啶-4-羧酸乙酯 淺黃色液體
©2025 萊陽市宇辰技術研發所 版權所有   技術支持:化工網   訪問量:7485  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |